

Supplemental Figure Legends

Supplemental Figure 1. Germline and somatic mutations in the *NF1* gene. (a) Table showing mutation positions compared to the canonical *NF1* gene transcript (ENST00000358273) and HS canonical protein product (ENSP00000351015). Reads showing reference sequence or variant alleles and the percent of variant reads were visually verified using IGV. (b) The location of predicted germline and somatic mutations in the canonical *NF1* protein detected in PNF and DNF. Same-position mutations found in different cohorts are marked.

Supplemental Figure 2. QQ plots of burden test and lollipop plots of some candidate germline mutated genes.

(a) Burden testing was performed using TRAPD and results were then visually represented by quantile-quantile (QQ) plots. Because ExAC samples and the case samples are not jointly processed and variant-called, the level of technical artifacts potentially introduced in this analysis (artifact inflation/deflation) were measured using the $\lambda_{\Delta 95}$ metric implemented in TRAPD. We detected small levels of inflation (i.e. above the optimal $\lambda_{\Delta 95} > 1.00$), likely due to the small case sample size and incomplete ancestry information. (b) Lollipop plots of *COL14A1*, *CELSR2*, *CUBN* and *FCGBP*. Each variant's functional impact was predicted by three bioinformatics tools and ClinVar dataset (see Methods and supplemental tables) but only effect predicted by SIFT was shown in the figure.

Supplemental Figure 3. Neurofibroma Schwann cell somatic variants. **(a)** Summary table of non-synonymous rare somatic variants in PNF and DNF datasets. (i.e. number and percent of patients harboring somatic variants from whole exome sequencing (WES) data from SC versus matched FB; percent of NF1 patients harboring variants in a WGS dataset from dermal neurofibroma versus matched blood, or in a WES dataset from PNF¹ **(Material and Methods)**). Notably, compared with low mutation ratio of the designated genes in cancers in COSMIC, these genes show a high percentage of variants in neurofibroma SCs, and also showed variants in the DNF² and/or PNF cohorts. Color bars on the right indicate the variant type, based on predicted effects on mRNA. Numbers are the number of tumors harboring variants in each gene in the PNFSC cohort. **(b)** Heat map of mRNA expression of those genes with expression level changes, in either tumor SC vs. normal SC and/or tumor tissue vs. nerve databases. **(c)** Lollipop plots showing the predicted effects of variants by SIFT on proteins. The genomic position of each variant detected in PNF was converted into the amino acid position of the corresponding protein product.

Supplemental Figure 4. Variants in *OBSCN* and *PKHD1L1*. **(a)** Summary table, Non-synonymous rare variants and the percentages of tumor samples with variants in these genes in PNF and DNF datasets **(b)** Gene variants are shown in 3 groups (I, II, and III); those with a germline variant and a 2nd allele somatic variant (I); germline variant only (II) or somatic variant only (III). FB: fibroblast; SC: Schwann cell. Color bars indicate variant types, based on predicted effects on the mRNA. Numbers at right of color bars are the total number of PNF (of 9) harboring variants in each gene. Individual neurofibromas

harbor different variants in *OBSCN* and *PKHD1L1* (i.e. for *OBSCN*, 1 neurofibroma showed a germline plus a second allele somatic mutations; 5 tumors harbored only a germline variant; 1 tumor sample harbored only a somatic variant). **(c)** Lollipop plots showing the predicted effects of variants on *OBSCN* and *PKHD1L1* protein function by SIFT. The genomic position of each variant detected in PNF was converted into the amino acid position of the corresponding protein product.

Supplemental Figure 5. Oncoprint analysis of candidate genes.

Oncoprint analysis of top 47 candidate (somatic and germline) genes in 9 PNF tumors generated by cBioPortal.

Supplemental Figure 6. Detailed description of *ATM* variants. Y: yes; N: Not found yet. The number (#) of databases that predicted a variant to be damaging.

Supplemental Figure 7. *ATM* germline variant confirmation, and proliferation in neurofibromas with *ATM* WT or *ATM* MU. (a, b) Sanger sequencing results for 2 different *ATM* germline variants. **(c)** Percent of Ki67 positive cells in neurofibromas with *ATM* MU vs. *ATM* WT (un-paired Student's *t*-test).

Supplemental Figure 8. Guide RNA and donor DNA sequences for variant construction, and shATM effects on SC growth. (a) *ATM* gene and amino acid sequence are highly conserved between human and mouse around the G2023R and S707P positions. In addition to a point mutation change in the donor DNA sequences, to

avoid Cas9 re-cutting we wobbled DNA sequences (green text) that were not predicted to change the amino acid sequence. In the donor DNA, there are ~50nt homology arms flanking the cut site. **(b, d)** sh*ATM* reduced *Atm* mRNA (RT-PCR) and ATM protein (western blot) in immortalized human Schwann cells (iHSC) and primary mouse embryonic SC (eSC). **(c, e)** sh*ATM* does not affect iHSC or eSC cell viability (MTS assays).

Supplemental Figure 9. Histological analysis of neurofibromas in *Nf1 fl/fl; DhhCre* and *Atm+/-; Nf1 fl/fl; DhhCre* mice. Neurofibromas were embedded in paraffin (n=10 tumors from 3 mice per genotype). **(a)** H&E staining, S100 marks SC, Toluidine blue metachromasia (purple) staining marks mast cells. **(b)** Statistical analysis of Toluidine blue+ mast cells/HPF (high power field) indicates an increased number of mast cells in neurofibromas from *Atm+/-; Nf1 fl/fl; DhhCre* mice. (Un-paired t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001)

SUPPLEMENTARY TABLES

Supplementary Table 1. Each sample's depth of coverage.

Supplementary Table 2. *NF1* gene Germline and somatic mutation status in NF1 patients

Supplementary Table 3: Top 22 genes showing germline variants

Supplementary Table 4: Top 25 genes showing somatic variants.

Supplementary Table 5: Germline variants in top 22 genes present in DNF² data

Supplementary Table 6: Somatic variants in top 25 genes present in DNF² data

Supplementary Table 7: Germline variants in top 22 genes present in PNF¹ data

Supplementary Table 8: Somatic variants in top 25 genes present in PNF¹ data

Supplementary Table 9: Datasets used for variant function prediction

Supplementary Methods

Germline Variant Calling

We considered the same rare and non-synonymous variant detected both in a SC sample and its matched FB sample as a probable germline mutation variant. Our “rare” variant filtering strategy is described below.

Somatic Variant Calling

Variant callers use different approaches to call variants, so we integrated results from methods described in Xu *et al*³. and Cai *et al*⁴. We used GATK-naiveSubtract, MuTect1, Strelka, SomaticSniper and VarScan2 to predict somatic point mutations (SNPs). INDELS were predicted using GATK-naiveSubtract, Strelka and VarScan2.

GATK-naiveSubtract The GATK-naiveSubtract method³ was used to call SNV and INDEL variants present in a SC sample VCF file but not in its matched control (FB) sample VCF file. Variants set for case and control samples were called independently using

GATK-HaplotypeCaller. For stringent filtering, we considered PASS-tagged variants passing $GQ > 20$ and $DP > 20$ cutoffs.

MuTect1 (v1.1.7) MuTect1⁵ detects SNPs only and is bundled into the GATK pipeline. To run this version of MuTect1, we used GATK v2.8 with java v1.7.0u40. We also used human genome (v37) bundled with GATK bundle 2.8. COSMIC v54 and dbSNP 132 (b37).

VarScan2 (v2.3.9) VarScan2⁶ detects SNPs, INDELs, and loss of heterozygosity events (LOH) in NGS data. SAMTOOLS v1.3 was used to make mpileup (-B q 1 -f). To perform somatic filtering, we used bam-readcount (-q 1 -b 20). After variant calling, we applied recommended somatic filters together with bam-readcount (-q 1 -b 20 -f). Java 1.8.0_40 was used to run this version of VarScan2.

Strelka (v1.0.15): Strelka⁷ detects SNPs and INDELs. SAMTOOLS v1.3, java v1.7.0u40 were used to run Strelka and a recommended built-in post-calling filter was used to remove possible false positives.

SomaticSniper (v1.0.5): SomaticSniper⁸ detects SNPs. SAMTOOLS v1.3 and bcftools v1.3 were used for the SomaticSniper pipeline. We set the somatic quality threshold of SomaticSniper to 15 (the author recommended 15-40). Raw call sets generated by SomaticSniper were filtered by pipelines proposed by the developers.

Variant Filtering Strategy We defined common variants (minor alternative reads ratio [MAF], $>1\%$) in a public data set as lower priority. We adopted dbSNP's GMAF $< 1\%$ and ExAC MAF $< 1\%$ as MAF-filtering criteria. If both MAF scores were $<1\%$, then we chose ExAC MAF. We also included possible novel variants that do not have defined MAF scores. We focused on non-synonymous variants found in protein coding canonical gene

transcript exon and splicing regions predicted to have HIGH / MODERATE / MODIFIER-impact functional effects. “HIGH” includes variants predicted to have disruptive impact on a protein, e.g. stop gained or frameshift variants causing protein truncation, loss of function or triggering nonsense mediated decay. “MODERATE” is a predicted non-disruptive variant that might change protein structure or function (e.g. missense variant, inframe deletion). “MODIFIER” includes predicted non-coding variants or variants affecting non-coding genes, where prediction is difficult or there is no evidence of impact; these were ignored in our analysis. We also ignored variants labeled “LOW”, alterations assumed to be harmless or unlikely to change protein behavior.

For somatic mutations, we considered HIGH, MODERATE, and MODIFIER-impact variants with min [GMAF < 1%, ExAC MAF < 1%], or novel. For germline mutations, we considered HIGH/MODERATE/MODIFIER-impact variants whose MAF < 1%. For analysis of the *NF1* gene, we considered HIGH- and MODERATE-impact variants satisfying these MAF-filtering criteria. The numbers of rare and non-synonymous HIGH, MODERATE, MODIFIER, and LOW-impact variants were plotted. Final variants were visually examined using an Integrative Genomics Viewer (IGV, <https://www software.broadinstitute.org/software/igv>).

Low-Complexity Regions. Based on 1,462,754 low-complexity region data (human v37 whole genome) predicted by mdust⁹, we checked +/- 20 nucleotide-long subsequences from called variant loci to determine if they fall into predicted low complexity regions. This does not mean the sequencing qualities of these variants are low. We used this information to prioritize candidates.

Variants effect prediction: Variant Annotation Variants from these 5 methods were annotated using Variant Effect Predictor (VEP) v83¹⁰ using Ensemble human genome (v37) and add-in databases and online algorithms including dbNSFP (v2.9)¹¹ and ClinVar (release: 20170104, <https://www.ncbi.nlm.nih.gov/clinvar/>)¹², dbSNP (v144, <https://www.ncbi.nlm.nih.gov/projects/SNP/>), Exome Aggregation Consortium (ExAC v0.3.1, <http://exac.broadinstitute.org/>), SIFT (v5.2.2), and HGMP-PUBLIC (v20152, <http://www.hgmd.cf.ac.uk/ac/index.php>). Annotated VCF files were converted to tab-delimited tables for data exploration using in-house PERL and BASH scripts. Mutation impact was annotated using ClinVar¹², SIFT¹³, MetaLR¹⁴ and MetaSVM¹⁴, included in the dbNSFP database (**Suppl. Table 9**).

MTS assay iHSC cells cultured in basic medium (10% Gem-Cell Fetal Bovine Serum in Gibco DMEM, 1% HyClone Penicillin-streptomycin solution) and primary mouse embryonic Schwann cells cultured in basic medium with 2uM forskolin (Calbiochem) and 10ng/ml β -heregulin (R&D system) were plated at 500 cells/well in 96 well plates (Corning, Black). After 3 days of culture, cell titer aqueous one solution for cell proliferation assay (Promega) was added to the wells according to the manufacturer's protocol. The plates then were read at 490nm absorbance 4 hours later. Three independent experiments with 5 replicates/sample in each experiment were performed and used for statistical analysis.

Un-paired t-test. To test if germline variants in the *ATM* gene cause differential effects to the total variants number, we calculated the Δ in number of total variants in SC vs. FB from each individual neurofibroma. We applied un-paired t-tests between the groups of

neurofibromas with and without *ATM* variants. The p-value is derived from calculated t-statistics. We used the t. test function, implemented in Prism.

Sanger sequencing primers for ATM germline variants confirmation:

Chr11: 108198394 C>A

Forward: TGGCAAAGCAGATGAGGAAAAC

Reverse: TCACTCCACCCTAGAGACTATACA

Chr11: 108098576 C>G

Forward: CTGCTGCCGTCAACTAGAACAT

Reverse: AAATGCCAAATTCATATGCAAGGC

Chr11: 108123621 T>G

Forward: ATGGTTGTCCTCCTTAAATTGTCCT

Reverse: AAACAACCTCTTCCCTGGCTAA

Full sequence of Donor DNA for G2023R:

AATTACTATCTAGAAAGTGCAGTTTACCTAGTAAGGGGTTGTAACATTTTCCCTCTC
CCGCAACCATACAGGCTGTCCGGCTCTCCTATACTTCTGTAGATCTCTAAGAGAAG
ATCCTGCAAACAGA

Full sequence of Donor DNA for S707P:

AACCCATAAATGCTCAAGAATACACCTGAATTCGTTTTAAGAAATCTCACCTCAGGA
GAATAGTTGCTTAAGAGCTGTTCTGATAATCCCAGAAGATAGTGATCCAATGATTCC
TTGAGATTTTGCT

Sanger sequencing primer for G2023R colony confirmation:

Forward: CTGCGTAAACTTCACTGATACAC

Reverse: TTCAAGTCTCTGCCTTTGGTATT

Sanger sequencing primer for S707P colony confirmation:

Forward: GCACTCCTTCCCACTAACCTA


Reverse: AAGTGAACAACACTGCGAAGATAA








Reference

1. Pemov, A. *et al.* The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas. *Oncogene* **36**, 3168-3177 (2017).
2. Gosline, S.J. *et al.* A high-throughput molecular data resource for cutaneous neurofibromas. *Sci Data* **4**, 170045 (2017).
3. Xu, H., DiCarlo, J., Satya, R.V., Peng, Q. & Wang, Y. Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. *BMC Genomics* **15**, 244 (2014).
4. Cai, L., Yuan, W., Zhang, Z., He, L. & Chou, K.C. In-depth comparison of somatic point mutation callers based on different tumor next-generation sequencing depth data. *Sci Rep* **6**, 36540 (2016).
5. Cibulskis, K. *et al.* Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. *Nat Biotechnol* **31**, 213-9 (2013).
6. Koboldt, D.C. *et al.* VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res* **22**, 568-76 (2012).
7. Saunders, C.T. *et al.* Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. *Bioinformatics* **28**, 1811-7 (2012).
8. Larson, D.E. *et al.* SomaticSniper: identification of somatic point mutations in whole genome sequencing data. *Bioinformatics* **28**, 311-7 (2012).
9. Li, H. Toward better understanding of artifacts in variant calling from high-coverage samples. *Bioinformatics* **30**, 2843-51 (2014).
10. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122 (2016).
11. Liu, X., Jian, X. & Boerwinkle, E. dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations. *Hum Mutat* **34**, E2393-402 (2013).
12. Landrum, M.J. *et al.* ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res* **42**, D980-5 (2014).
13. Ng, P.C. & Henikoff, S. Predicting deleterious amino acid substitutions. *Genome Res* **11**, 863-74 (2001).
14. Dong, C. *et al.* Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. *Hum Mol Genet* **24**, 2125-37 (2015).

a NF1 germline and somatic mutation status in different NF1 patients

Sample	Position	REF	ALT	Effect	HGMD ID	ClinVar	Cell type	Status	Reads with reference allele(FB/SC)	Reads with mutation allele(FB/SC)	% of mutation reads
T1	17:29652983	A	T	stop gained			FB/SC	germline	42/53	48/52	53/50
	17:29664575	C	G	missense			SC	somatic	79	37	47
	17:29664862	G	T	missense			SC	somatic	41	4	9
T2	17:29562746	C	G	missense	CM040785	likely pathogenic	FB/SC	germline	35/33	36/34	51/51
	17:29509674	CATGAAT AAGGTA	C	splicing			SC	somatic	35	7	16
	17:29677252	G	T	missense			SC	somatic	117	6	5
T3	17:29497003	C	T	stop gained	CM000774	pathogenic	SC	somatic	52	13	25
T4	17:29585518	A	G	missense		pathogenic	FB/SC	germline	79/44	61/39	44/47
	17:29556042	G	A	splicing		pathogenic	SC	somatic	35	6	15
T5a	17:29483145	G	A	splicing		pathogenic	FB/SC	germline	109/136	116/109	51/44
	17:29533315	C	T	stop gained	CM000780	pathogenic	SC	somatic	192	85	44
T5c	17:29483145	G	A	splicing		pathogenic	FB/SC	germline	118/210	130/118	52/36
	17:29562641	C	T	stop gained	CM000799	pathogenic	SC	somatic	191	32	14
T6	17:29560021	C	T	splicing/synonymous			FB/SC	germline	41/12	29/46	41/79
	17:29546122	C	T	stop gained	CM020463	pathogenic	SC	somatic	74	20	21
	17:29556143	G	A	stop gained	CM076345	pathogenic	SC	somatic	41	8	16
T7	17:29557401	G	A	splicing		pathogenic	FB/SC	germline	42/0	34/67	45/100
	17:29557401	G	A	splicing		pathogenic	SC	Somatic (LOH)	0	67	100
T8	17:29677208	T	TA	frame shift		pathogenic	FB/SC	germline	272/276	104/116	28/30
	17:29562709	AG	A	frame shift			SC	somatic	147	73	50




a**b****COL14A1****FCGBP****CELSR2****CUBN**



a

Gene Symbol	# of PNFS tumor with			PNFS % NF1 patients with variants	DNF <i>Gosline et al</i> % NF1 patients with variants	PNF <i>Pemov et al</i> % NF1 patients with variants	COSMIC % with mutations
	I	II	III				
DMXL2			3	33	8		3.2
FREM2			3	33			5.0
AMOT			3	33			0.7
DOCK1			3	33			4.9
DOCK10			3	33		5	4.4
ESRRB			3	33			0.7
GPC4			3	33			1.8
HMCN1			3	33			9.5
MDN1			3	33		5	4.3
PPP2R3A			3	33			2.1
PTPRS			3	33			2.1
SLC4A7			3	33			1.5
AGAP2			2	22			0.8
DENND2C			2	22			1.2
ITGB8			2	22			2.0
KIAA1432			2	22			1.7
MACF1			2	22	15		3.9
MYH9			2	22	8		2.5
PHOSPHO1			2	22			0.1
RNF213			2	22			2.4
RREB1			2	22		5	1.3
SCN10A			2	22			3.9

III Somatic Only Variants



**b**



Somatic Variants

**c**

a

Gene Symbol	# of PNF tumors with			% NF1 patients with variants in PNF	% NF1 patients with variants in syn4984604 DNF
	I	II	III		
NF1	8	0	1	100	31
OBSCN	1	5	1	78	39
PKHD1L1	2	3	1	67	39

b**c**






Genetic Alteration

- Splicing Mutation
- Truncating Mutation
- Missense Mutation

Detailed Description of ATM genomic Variants in neurofibromas

Gene Symbol	Variants HGVS	Variant sample	Found in A-T Patients	Found in Breast Cancer	Found in Other Cancer type(s)	# of Datasets Predicted as Damaging	Known effects on Protein function or Tumorigenesis	Reference (PMID)
ATM	ENSP00000278616.4 :p.Ser49Cys	PNF(This study & PemoV)	Y	Y	Y(Melonoma, Prostate cancer and oropharyngeal cancer)	3	May be breast cancer susceptibility allele; associated with other types of cancers; undertermined for protein function.	16652348; 18565893; 8665503; 10534763
	ENSP00000278616.4 :p.Phe858Leu	PNF(This study)	Y	Y	Y(Lymphoma)	2	Increased risk for breast cancer development; no known risk for other cancers. May associate with LOH in breast cancer.	8797579; 10534763; 20826828; 12149228
	ENSP00000278616.4 :p.Gly2023Arg	PNF(This study)	Y	Y	Y(Lymphoma)	6	Loss of protein expression	27664052; 12149228; 23091097; 9005288
	ENSP00000278616.4 :p.Met1210Val	DNF(Gosline)	N	N	Y(Liver Cancer)	3	Unknown significance	COSMIC
	ENSP00000278616.4 :p.Val2079Ile	DNF(Gosline)	N	Y	N	0	Associated with loss of rare allele	19781682; 12917204; 8665503
	ENSP00000278616.4 :p.Leu2332Pro	DNF(Gosline)	N	N	N	2	Mutated in FAT domain	COSMIC; 28492532; 17344846
	ENSP00000278616.4 :p.Phe627Cys	PNF(PemoV)	N	Y	N	3	Unknown significance	COSMIC; 28492532; 19781682
	ENSP00000278616.4 :p.Ala740Thr	PNF(PemoV)	N	N	N	7	Unknown significance	N/A
	ENSP00000278616.4 :p.Thr2333Lys	PNF(PemoV)	N	N	N	1	Mutated in FAT domain	COSMIC; ClinVar; 28492532
	ENSP00000278616.4 :p.Cys2464Arg	PNF(PemoV)	N	Y	Y(Chronic Lymphocytic Leukemia, colorectal carcinomas)	3	Doesn't interfere with ATM kinase function	19781682; 17344846; 11805335; 27756406
ENSP00000278616.4 :p.Ser707Pro	PNF(PemoV)	N	Y	Y(Lymphoma, Thyroid or endocrine cancers, Lung cancer)	0	Associated with increased risk of thyroid or endocrine cancers.	27413114; 18164969; 20826828	



a**Atm G2023R**

5' GAGCCAGATAGTTTGTATGGCTGTGGTGGAGGGAAGATGTTACAACCC 3' Human DNA seq
 5' GAGCCGGACAGCCTGTATGGCTGTGGA GGA GGGAAAATGTTACAACCC 3' Mouse DNA seq
 E--P--D--S--L--Y--G--C--G--G--G--K--M--L--Q--P-- AA sequence

gRNA sequence GCCTGTATGGCTGTGGAGGA

Donor DNA sequence 3' --GCCTGTATGGT T GCGGGA GA --- 5' ~100nt total length

Atm S707P

5' AATTACTCATCTGAGATTACA 3' Human DNA seq





5' AATTACTCT T CTGAGATTACA 3' Mouse DNA seq







N--Y--S--S--E--I--T-- AA sequence

gRNA sequence TTTAAGTAATTACTCTTCTGAGG


Donor DNA sequence 3' --CTTAAGCAACTAT T TCTCTGAGG --- 5' ~100nt total length

█ Variant site █ PAM site █ Green Text Wobbled DNA Sequence --- Homology Arm █ Blue Text Next Exon

b**c****d****e**

a**H&E****S100****Toluidine blue***Nf1 fl/fl; DhhCre**Atm +/-; Nf1 fl/fl;**DhhCre***b**

Toluidine blue+ cells/HPF



Supplementary Table 1. Each sample's depth of coverage.

GATK coverage info		
	Fibroblast	Schwann cell
Sample	*Depth of Coverage	*Depth of Coverage
T1	79.2	75.4
T2	82.8	100.8
T3	50.5	59.9
T4	98.4	80.2
T5a	118.6	117.2
T5c	101.9	143.8
T6	101.5	128.9
T7	122.2	111.0
T8	149.8	152.6
P9		97.4
Mean	100.6	106.7
Max.	149.8	152.6
Min.	50.5	59.9

*Sum of the sample specific depth in all loci divided by interval size

Supplementary Table 2 NF1 gene Germline and somatic mutation status in different NF1 patients--Extended														Variants with deleterious, damaging, and/or pathogenic effect (see Suppl. Table 9)						
sample	position (Chr. site)	Ref. Genotype	Mut. Genotype	Effect	HGMD ID	Cell type	Status	Reads with reference allele (FB/SC)	Reads with mutation allele (FB/SC)	% of mutation reads	GMAF/ ExAC MAF	1000Gp1_AC	COSMIC_ID	HGVSc	HGVSp	ClinVar disease	ClinVar	SIFT	MetaLR	MetaSVM
T1	17:29652983	A	T	stop gained		FB/sc	germline	42/53	48/52	53/50				ENST00000358273.4:c.4981A>T	ENSP00000351015.4:p.Lys1661Ter		-		-	-
	17:29664575	C	G	missense		SC	somatic	79	37	47				ENST00000358273.4:c.6617C>G	ENSP00000351015.4:p.Thr2206Arg		-	deleterious	T	T
	17:29664862	G	T	missense		SC	somatic	41	4	9							-	deleterious	T	T
T2	17:29562746	C	G	missense	CM040785	FB/SC	germline	35/33	36/34	51/51				ENST00000358273.4:c.3826C>G	ENSP00000351015.4:p.Arg1276Gly	NF1	pathogenic	deleterious	D	D
	17:29509674	CATGAATAAG	C	splicing		SC	somatic	35	7	16				ENST00000358273.4:c.881_888+4delTGAATAAGGTAA			-		-	
	17:29677252	GTA	T	missense		SC	somatic	117	6	5							-	deleterious	T	T
T3	17:29457003	C	T	stop gained	CM000774	SC	somatic	52	13	25	0.00008238		COSM42794	ENST00000358273.4:c.574C>T	ENSP00000351015.4:p.Arg192Ter	NF1	pathogenic			-
T4	17:29585518	A	G	missense		FB	germline	79/44	61/39	44/47	8.24E-06		COSM24576	ENST00000358273.4:c.4330A>G	ENSP00000351015.4:p.Lys1444Glu	NF1	pathogenic	deleterious	D	D
T5a	17:29483145	G	A	splicing		FB	germline	109/136	116/109	51/44				ENST00000358273.4:c.204-1G>A			likely pathogenic		-	
	17:29533315	C	T	stop gained	CM000780	SC	somatic	192	85	44	8.24E-06		COSM977403	ENST00000358273.4:c.1318C>T	ENSP00000351015.4:p.Arg440Ter	NF1	pathogenic			-
T5c	17:29483145	G	A	splicing		FB	germline	118/210	130/118	52/36				ENST00000358273.4:c.204-1G>A			pathogenic		-	
	17:29562641	C	T	stop gained	CM000799	SC	somatic	191	32	14			COSM24441	ENST00000358273.4:c.3721C>T	ENSP00000351015.4:p.Arg1241Ter	NF1	pathogenic			-
T6	17:29560021	C	T	splicing/synonymous		FB	germline	41/12	29/46	41/79	0.0044/1.244E-03			ENST00000358273.4:c.3498C>T	ENST00000358273.4:c.3498C>T(p.%3D)	NF1				-
	17:29546122	C	T	stop gained	CM020463	SC	somatic	74	20	21				ENST00000358273.4:c.1627C>T	ENSP00000351015.4:p.Gln543Ter		-			-
T7	17:29556143	G	A	stop gained	CM076345	SC	somatic	41	8	16				ENST00000358273.4:c.2510G>A	ENSP00000351015.4:p.Trp837Ter		-			-
	17:29557401	G	A	splicing		FB	germline	42/0	34/67	45/100				ENST00000358273.4:c.3113+1G>A		NF1	pathogenic			-
T8	17:29677208	T	TA	frame shift		SC	germline and somatic	0	67	100						NF1	pathogenic			-
	17:29562709	AG	A	frame shift		SC	somatic	272/276	104/116	28/30				ENST00000358273.4:c.7330dupA	ENSP00000351015.4:p.Thr2444AsnfsTer4		-			-
								147	73	50				ENST00000358273.4:c.3790delG	ENSP00000351015.4:p.Glu1264LysfsTer2		-			-

End note: Highlighted sites are recurrent mutation with same site on same gene in different PNF (Ratner), DNF (Gosline) and PNF (Pemov) samples

Yellow: Overlapped mutated sites between PNF (Ratner) and DNF (Gosline)

Green: Overlapped mutated sites between PNF (Ratner) and PNF (Pemov)

Supplementary Table 3: Top 22 germline variant genes

SYMBOL	CHR	POS	Sample #	Ref	Alt	Consequences	HGVS	HGVS_p	GMAF	ExAC_MAF	1000Gp1_A C allele counts in	ExAC_A C allele counts in	INFO	Reads with reference	Reads with mutation	Mutation reads Ratio(FB)	Reads with allele(SC)	Reads with mutation(SC)	Mutation Ratio(SC)	ClinVar (2019)	SIFT	MetaLR	MetaSVM	Variants with deleterious, damaging, and/or pathogenic effect (see Suppl. Table 6)																		
																								Likely_pathogenic	Pathogenic																	
NF1	17	2965283	T1	A	T	stop_gained	ENST00000358273.4:c.4981A>T	ENSP0000035105.4p.Lys1461Ter	-	-	-	-	-	42	48	53%	53	52	50%																							
									29652746	G	C	missense_variant	ENST00000358273.4:c.4826C>G	ENSP0000035105.4p.Arg1276Gly	-	-	1	1	100%	35	36	51%	33	34	51%	Likely_pathogenic	deleterious	-	-	D	D											
									29655518	G	A	missense_variant	ENST00000358273.4:c.4388A>C	ENSP0000035105.4p.Arg1444Glu	A:0.00000824	-	-	-	-	63	63	44%	44	39	44%	44	39	44%	Pathogenic	deleterious	-	-	D	D								
									29483145	T5a	G	A	splice_donor_variant	ENST00000358273.4:c.204-16GA	-	-	-	-	-	-	116	109	48%	109	136	55%	Pathogenic	-	-	-	-	-	-									
									29483145	T5a	G	A	splice_donor_variant	ENST00000358273.4:c.204-16GA	-	-	-	-	-	-	116	109	48%	109	136	55%	Pathogenic	-	-	-	-	-	-									
COL14A1	8	121354634	T2	C	G	missense_variant	ENST00000297848.3:c.4837C>G	ENSP00000297848.3p.Arg1613Glu	G:0.0014	G:1.581e-03	3	192	192	r140154122	95	123	56%	53	52	50%																						
									121325981	T1	C	missense_variant	ENST00000297848.3:c.4898A>C	ENSP00000297848.3p.Arg1627Tyr	C:0.0002	C:1.002e-03	17	129	129	r1116691414	96	23	28%	65	44	28%	44	39	47%	Pathogenic	deleterious	-	-	D	D							
									121325981	T5a	G	A	missense_variant	ENST00000297848.3:c.2764G>A	ENSP00000297848.3p.Arg1202Gln	A:0.0028	A:3.2e-07	10	837	837	r111774228	79	42	35%	79	42	35%	Pathogenic	deleterious	-	-	D	D									
									121293179	T5a	G	A	missense_variant	ENST00000297848.3:c.3705G>A	ENSP00000297848.3p.Met1235Ile	-	-	-	-	-	968	102	51%	109	71	26%	46%	79%	Pathogenic	deleterious	-	-	D	D								
									121267490	T5c	G	A	missense_variant	ENST00000297848.3:c.2764G>A	ENSP00000297848.3p.Val922Ile	A:0.0028	A:3.27e-03	10	637	637	r111774228	57	72	56%	89	56	39%	Pathogenic	deleterious	-	-	D	D									
									121293179	T5c	G	A	missense_variant	ENST00000297848.3:c.3705G>A	ENSP00000297848.3p.Met1235Ile	-	-	-	-	-	968	102	51%	109	71	26%	46%	79%	Pathogenic	deleterious	-	-	D	D								
									121256190	T6	G	A	missense_variant	ENST00000297848.3:c.2425A>G	ENSP00000297848.3p.Val808Met	A:0.0004	A:3.765e-05	7	129	129	r115766614	40	67	60%	53	29	38%	38%	42%	Pathogenic	deleterious	-	-	D	D							
									121293179	T6	G	A	missense_variant	ENST00000297848.3:c.3705G>A	ENSP00000297848.3p.Met1235Ile	-	-	-	-	-	968	102	51%	109	71	26%	46%	79%	Pathogenic	deleterious	-	-	D	D								
									111118382	T3	G	A	missense_variant	ENST00000360467.5:c.2016G>A	ENSP00000360467.5p.Ile85Val	A:0.0012	A:5.954e-04	4	72	72	r143710874	99	95	49%	198	144	42%	42%	49%	Pathogenic	deleterious	-	-	D	D							
									111114695	T3a	T	A	missense_variant	ENST00000360467.5:c.1740T>A	ENSP00000360467.5p.Arg500Glu	-	-	-	-	-	1	30	30	50%	43	49	59%	54	49	59%	Pathogenic	deleterious	-	-	D	D						
									111114695	T3a	T	A	missense_variant	ENST00000360467.5:c.1740T>A	ENSP00000360467.5p.Arg500Glu	-	-	-	-	-	1	30	30	50%	43	49	59%	54	49	59%	Pathogenic	deleterious	-	-	D	D						
									111155479	T6	C	T	missense_variant	ENST00000360467.5:c.3889C>T	ENSP00000360467.5p.Arg1295Tyr	T:0.0006	T:1.821e-04	2	22	22	r187356494	27	14	27%	12	16	57%	12	16	57%	Likely_benign	-	-	-	-	-						
									111154563	T6	T	C	3_prime_UTR_variant	ENST00000360467.5:*25T>C	C:0.0088	C:2.905e-03	2	22	22	r113311483	27	14	27%	12	16	57%	12	16	57%	Likely_benign	-	-	-	-	-							
									111143601	T8	A	G	missense_variant	ENST00000360467.5:c.3388A>G	ENSP00000360467.5p.Glu1230Val	G:0.0058	G:7.829e-03	18	945	945	r111741802	79	75	49%	87	59	40%	40%	49%	Pathogenic/Likely_benign_risk	deleterious	-	-	D	D							
									MAST4	5	6641069	T2	G	A	missense_variant	ENST00000436623.2:c.2956G>A	ENSP0000038727.1p.Glu868Ile	A:0.0036	A:9.205e-03	7	114	114	r55969676	33	25	43%	36	38	51%	Pathogenic	deleterious	-	-	D	D							
6641391	T3	G	C	missense_variant	ENST00000436623.2:c.6948G>C	ENSP0000038727.1p.Arg1285Ser	C:0.0002	A:2.295e-08										1	9	202	r77191584	16	31	66%	55	29	35%	Pathogenic	deleterious_low_confidence	-	-	D	D									
6642049	T3	G	C	missense_variant	ENST00000436623.2:c.7394G>C	ENSP0000038727.1p.Arg1293Tyr	G:0.0052	G:4.432e-03										6	172	172	r533802014	39	17	30%	47	24	42%	Pathogenic	deleterious_low_confidence	-	-	D	D									
6589245	T5a	C	A	5_prime_UTR_variant	ENST00000436623.2:c.39C>A	A:0.0002	A:4.756e-04	1										8	8	-	11	11	50%	4	6	60%	4	6	60%	Pathogenic	deleterious	-	-	D	D							
6589245	T5c	C	A	5_prime_UTR_variant	ENST00000436623.2:c.39C>A	A:0.0002	A:4.756e-04	1										8	8	-	8	3	27%	10	11	52%	10	11	52%	Pathogenic	deleterious	-	-	D	D							
MUC16	19	9046071	T1	C	T	missense_variant	ENST00000397910.2:c.2445A>G	ENSP0000038727.1p.Arg1308Gly	T:0.0006	T:2.482e-05	12	15	15	r201605728	82	78	49%	43	45	43%	Pathogenic	deleterious	-	-	D	D																
									9065094	T2	T	C	missense_variant	ENST00000397910.2:c.2235T>G	ENSP0000038727.1p.Arg1389Gln	C:0.0006	C:1.389e-03	6	87	87	r115107458	40	39	40%	42	52	52%	Pathogenic	deleterious	-	-	D	D									
									9096341	T3	G	A	missense_variant	ENST00000397910.2:c.1908S>C	ENSP0000038727.1p.Arg1302Cys	A:0.0086	A:2.655e-03	11	321	321	r115200029	381	222	37%	584	373	39%	Pathogenic	deleterious	-	-	D	D									
									9073300	T3	C	A	missense_variant	ENST00000397910.2:c.1414G>A	ENSP0000038727.1p.Arg1476Ser	A:0.0016	A:3.474e-04	3	42	42	r116257308	47	35	43%	69	48	41%	Pathogenic	deleterious	-	-	D	D									
									9068983	T5a	G	T	missense_variant	ENST00000397910.2:c.4832C>A	ENSP0000038727.1p.Trp1811Ile	T:0.0010	T:2.696e-03	3	328	328	r180451266	78	84	48%	90	88	49%	Pathogenic	deleterious	-	-	D	D									
									9068983	T5a	G	T	missense_variant	ENST00000397910.2:c.4832C>A	ENSP0000038727.1p.Trp1811Ile	T:0.0010	T:2.696e-03	3	328	328	r180451266	78	84	48%	90	88	49%	Pathogenic	deleterious	-	-	D	D									
									9002059	T8	T	C	missense_variant	ENST00000397910.2:c.4743G>A	ENSP0000038727.1p.Arg1479Gly	C:0.0016	C:5.691e-03	2	326	326	r120453110	117	117	50%	117	114	48%	110	110	48%	Pathogenic	deleterious	-	-	D	D						
									9068458	T8	T	C	missense_variant	ENST00000397910.2:c.4743G>A	ENSP0000038727.1p.Arg1479Gly	T:0.0016	T:5.458e-03	4	660	660	r150142305	164	168	51%	148	154	44%	144	144	44%	Pathogenic	deleterious	-	-	D	D						
									OBSCN	1	128680779	T1	G	A	missense_variant	ENST0000070156.2:c.2517G>A	ENSP000005507.2p.Glu831Ile	A:0.0002	A:3.439e-04	4	40	40	r19907775	4	10	71%	5	5	50%	Pathogenic	deleterious	-	-	D	D							
																		22857793	T2	G	A	missense_variant	ENST0000070156.2:c.2295G>A	ENSP000005507.2p.Arg763Tyr	A:0.0024	A:2.200e-03	5	272	272	r145597580	38	29	34%	82	65	44%	Pathogenic	deleterious	-	-	D	D
																		22847833	T5c	C	T	missense_variant	ENST0000070156.2:c.1034G>T	ENSP000005507.2p.Ser449Phe	A:0.0002	A:1.632e-04	1	3	3	-	31	45%	39	39	44%	Pathogenic	deleterious	-	-	D	D	
																		228430967	T6	G	A	missense_variant	ENST0000070156.2:c.3289G>A	ENSP000005507.2p.Glu1097Tyr	A:0.0002	A:1.323e-04	1	16	16	-	44	34	42%	50	54	52%	Pathogenic	deleterious	-	-	D	D
																		228407017	T7	C	T	ice_region_variant&intron_variant	ENST0000070156.2:c.2654-8C>T	T:0.0002	T:2.482e-05	-	-	-	-	14	11	44%	4	9	69%	4	9	69%	Pathogenic	deleterious	-	-
									ANRD30A	10	3741455	T1	C	T	5_prime_UTR_variant	ENST0000036171.1:c.29C>T	ENSP0000034412.1p.Arg78Tyr	T:0.0084	T:2.358e-03	15	34	34	r74412113	15	34	69%	49	43	47%	Pathogenic	deleterious	-	-	D	D							
																		3742294	T6	A	G	missense_variant	ENST0000036171.1:c.540A>G	ENSP0000034412.1p.Ile180Met	G:0.0002	G:9.432e-04	5	114	114	r190021267	123	108	47%	99	121	55%	Pathogenic	deleterious	-	-	D	D
3750878	T1	CTG	C	frameshift_variant	eITG	ENSP0000034412.1p.Ile180Met	-	-										-	-	-	-	-	-	-	-	-	-	-	-	-	-											
37482182	T7	AG	A	frameshift_variant	eITG	ENSP0000034412.1p.Ile180Met	-	-										-	-	-	-	-	-	-	-	-	-	-	-	-	-	-										
16893406	T3	G	C	missense_variant	ENST0000037833.4:c.949G>C	ENSP0000037833.4p.Arg314Tyr	G:0.0078	A:3.295e-06										10	342	342	r57163341	18	20	61%	28	31	53%	Pathogenic	deleterious	-	-	D	D									
CUBN	10	17112656	T1	C	T	missense_variant	ENST0000037833.4:c.254A>G	ENSP0000037833.4p.Arg85Gln	A:0.0002	A:3.765e-05	1	904	904	r113085122	85	101	56%	86	78	48%	Pathogenic	deleterious	-	-	D	D																
									16957036	T5a	A	G	missense_variant	ENST0000037833.4:c.7344T>C	ENSP0000037833.4p.Met2449Tyr	G:0.0034	C:3.542e-04	3	529	529	r143101097	58	28	33%	68	38	36%	Benign	deleterious	-	-	D	D									
									16957036	T5c	A	G	missense_variant	ENST0000037833.4:c.7344T>C	ENSP0000037833.4p.Met2449Tyr	G:0.0034	C:3.542e-04	3	529	529	r143101097	47	40	46%	62	52	46%	Benign	deleterious	-	-	D	D									
									168692																																	

Supplementary Table 4: Top 25 somatic variant genes																	Variants with deleterious, damaging, and/or pathogenic effect (see Suppl. Table 9)				
Symbol	Chr#	Position	Ref	Alt	mutation type	HGVSc	HGVSp	Patient #	Reads with reference allele	Reads with mutation	Mutation reads ratio	GMAF/Exac MAF	1000Gp1_AC allele counts in 1000	ExAC_AC allele counts in ~60,706	DOMAIN	COSMIC_ID	ClinVar (2019)	SIFT	MetaLR	MetaSVM	
NF1	17	29664575	C	T	missense	ENST00000358273.4:c.6617C>G	ENSP00000351015.4:p.Thr2206Arg	T1	79	37	47%	-	-	-	Superfamily_domains:SSF4837	-	Uncertain	deleterious	T	T	
	17	29664862	G	T	missense	ENST00000358273.4:c.6668G>T	ENSP00000351015.4:p.Cys223Phe	T1	41	4	9%	-	-	-	Superfamily_domains:SSF4837	-	deleterious	T	T		
	17	29509674	CATGAATAAGGTA	C	splicing	ENST00000358273.4:c.881_888+4delTGAATAAGGTAA	-	T2	35	7	16%	-	-	-	-	-	-	-	-	-	
	17	29677252	G	T	missense	ENST00000358273.4:c.7379G>T	ENSP00000351015.4:p.Arg2458Ile	T2	117	6	5%	-	-	-	hmmpanther:PTRH10194:SF600	-	-	deleterious	T	T	
	17	29497003	C	T	stop gained	ENST00000358273.4:c.574C>T	ENSP00000351015.4:p.Arg192Ter	T3	52	13	25%	0.00008238	-	1	hmmpanther:PTRH10194:SF600	COSM42794	Pathogen	-	-	-	-
	17	29556042	G	A	splicing	ENST00000358273.4:c.2410-1G>A	-	T4	35	6	15%	-	-	-	-	-	-	-	-	-	-
	17	29533315	C	T	stop gained	ENST00000358273.4:c.1318C>T	ENSP00000351015.4:p.Arg440Ter	T5a	192	85	44%	8.24E-06	-	-	hmmpanther:PTRH10194:SF600	COSM977403	Pathogen	-	-	-	-
	17	29562641	C	T	stop gained	ENST00000358273.4:c.1015G>A	ENSP00000351015.4:p.Arg1241Ter	T5c	191	32	14%	-	-	-	Superfamily_domains:SSF4835	COSM24441	Pathogen	-	-	-	-
	17	29556143	G	A	stop gained	ENST00000358273.4:c.2510G>A	ENSP00000351015.4:p.Trp837Ter	T6	41	8	16%	-	-	-	hmmpanther:PTRH10194:SF600	-	Pathogen	-	-	-	-
	17	29546122	C	T	stop gained	ENST00000358273.4:c.1627C>T	ENSP00000351015.4:p.Gln543Ter	T6	74	20	21%	-	-	-	hmmpanther:PTRH10194:SF600	-	Pathogen	-	-	-	-
17	29557401	G	A	splicing(LOH)	ENST00000358273.4:c.3113+1G>A	-	T7	0	67	100%	-	-	-	-	-	-	-	-	-	-	
17	29562709	AG	A	frame shift	ENST00000358273.4:c.3790delG	ENSP00000351015.4:p.Glu1264LysfTs	T8	147	73	50%	-	-	-	-	Superfamily_domains:SSF4835	-	-	-	-	-	
DMXL2	15	51756891	G	T	missense	ENST00000543779.2:c.7789C>A	ENSP00000441858.2:p.Pro2597Thr	T2	53	6	10%	-	-	-	hmmpanther:PTRH13950:SF110	-	-	deleterious	T	T	
	15	51741351	T	A	stop gained	ENST00000543779.2:c.8944A>T	ENSP00000441858.2:p.Lys2982Ter	T3	61	6	9%	-	-	-	Superfamily_domains:SSF5097	-	-	-	-	-	
	15	51792221	A	G	missense	ENST00000543779.2:c.3200T>A	ENSP00000441858.2:p.Ile1067Asn	T4	110	6	5%	-	-	-	hmmpanther:PTRH13950:SF110	-	-	deleterious	T	T	
	15	51829806	A	G	missense	ENST00000543779.2:c.1496T>C	ENSP00000441858.2:p.Leu499Pro	T4	139	7	5%	-	-	-	Superfamily_domains:SSF5097	-	-	deleterious	T	T	
FREM2	13	39262630	C	A	missense	ENST00000280481.7:c.1149C>A	ENSP00000280481.7:p.Phe383Leu	T1	114	8	7%	-	-	-	hmmpanther:PTRH11878&hmn	-	-	deleterious	T	T	
	13	39422643	C	A	missense	ENST00000280481.7:c.6215C>A	ENSP00000280481.7:p.Pro2072His	T1	108	6	5%	-	-	-	hmmpanther:PTRH11878&hmn	-	-	deleterious	T	T	
	13	39422747	A	T	missense	ENST00000280481.7:c.6319A>T	ENSP00000280481.7:p.Asn2107Tyr	T3	137	8	6%	-	-	-	hmmpanther:PTRH11878&hmn	-	-	deleterious	T	T	
	13	39452288	C	T	missense	ENST00000280481.7:c.8689C>T	ENSP00000280481.7:p.Arg2897Cys	T4	114	12	10%	-	-	-	hmmpanther:PTRH11878&hmn	-	-	deleterious	D	D	
AMOT	X	112035168	C	A	missense	ENST00000371959.3:c.1818G>T	ENSP00000361027.3:p.Met601Ile	T1	64	4	6%	-	-	-	Coiled-coils_(Ncoils):Coil&hmi	-	-	-	-	-	
	X	112022711	C	A	missense	ENST00000371959.3:c.2671G>T	ENSP00000361027.3:p.Ala891Ser	T3	190	14	7%	-	-	-	Low_complexity_(Seg):seg&hnr	-	-	-	-	-	
	X	112054600	C	T	missense	ENST00000371959.3:c.1414G>A	ENSP00000361027.3:p.Val472Ile	T5a	167	11	6%	-	-	5	Coiled-coils_(Ncoils):Coil&hmi	-	-	-	-	-	
DOCK1	10	129237467	A	G	missense	ENST00000280333.6:c.5174A>G	ENSP00000280333.6:p.Glu1725Gly	T5a	146	8	5%	-	-	-	-	-	-	tolerated	T	T	
	10	12913732	C	T	missense	ENST00000280333.6:c.3044C>T	ENSP00000280333.6:p.Ala1015Val	T7	86	10	10%	-	-	-	hmmpanther:PTRH23317&hmn	-	-	tolerated	T	T	
	10	12924274	C	T	missense	ENST00000280333.6:c.5285C>T	ENSP00000280333.6:p.Pro1762Leu	T8	198	17	8%	-	-	1	Low_complexity_(Seg):seg	-	-	tolerated	T	T	
DOCK10	2	225710266	C	A	missense	ENST00000258390.7:c.2329G>T	ENSP00000258390.7:p.Ala775Ser	T1	159	8	5%	-	-	-	Low_complexity_(Seg):seg&PF	-	-	tolerated	T	T	
	2	225727425	G	T	stop gained	ENST00000258390.7:c.1641C>A	ENSP00000258390.7:p.Cys547Ter	T2	64	6	9%	-	-	-	hmmpanther:PTRH23317:SF710	-	-	-	-	-	
	2	225738724	G	C	missense	ENST00000258390.7:c.1246C>G	ENSP00000258390.7:p.Pro416Ala	T3	156	9	5%	-	-	-	hmmpanther:PTRH23317:SF710	-	-	tolerated	T	T	
ESRRB	14	76905924	C	G	stop gained	ENST00000380887.2:c.228C>G	ENSP00000370270.2:p.Tyr76Ter	T1	34	4	11%	-	-	-	hmmpanther:PTRH24084&hmn	-	-	-	-	-	
	14	76957895	A	G	missense	ENST00000380887.2:c.893A>G	ENSP00000370270.2:p.Lys298Arg	T4	73	6	8%	-	-	-	hmmpanther:PTRH24084&hmn	-	-	tolerated	D	D	
	14	76964736	G	A	missense	ENST00000380887.2:c.1237G>A	ENSP00000370270.2:p.Val131Ile	T8	27	6	18%	-	-	12	1336	hmmpanther:PTRH24084&hmn	-	Benign/Li	tolerated	T	T
GPC4	X	132427211	C	A	missense	ENST00000370828.3:c.216G>T	ENSP00000359864.3:p.Glu72Asp	T1	82	6	7%	-	-	-	hmmpanther:PTRH10822:SF250	-	-	deleterious	T	T	
	X	132440114	A	G	missense	ENST00000370828.3:c.1451T>C	ENSP00000359864.3:p.Val484Ala	T3	116	6	5%	-	-	-	hmmpanther:PTRH10822:SF250	-	-	deleterious	T	T	
	X	132473314	C	A	missense	ENST00000370828.3:c.946G>T	ENSP00000359864.3:p.Asp316Tyr	T8	75	39	34%	-	-	-	hmmpanther:PTRH10822:SF250	-	-	deleterious	T	T	
HMCN1	1	185953439	G	T	missense	ENST00000271588.4:c.2929G>T	ENSP00000271588.4:p.Val977Leu	T1	151	11	7%	-	-	-	hmmpanther:PTRH19897:SF150	-	-	deleterious	D	D	
	1	185946996	C	T	stop gained	ENST00000271588.4:c.2449C>T	ENSP00000271588.4:p.Gln817Ter	T4	137	13	9%	-	-	-	PROSITE_profiles:P550835&hmi	-	-	-	-	-	
	1	185891512	C	T	missense	ENST00000271588.4:c.902C>T	ENSP00000271588.4:p.Thr301Ile	T5a	65	6	8%	-	-	-	hmmpanther:PTRH19897:SF150	-	-	tolerated	T	T	
MDN1	6	90497672	G	T	missense	ENST00000369393.3:c.1235C>A	ENSP00000358400.3:p.Ser412Tyr	T2	71	5	7%	-	-	-	hmmpanther:PTRH22908:SF580	-	-	deleterious	T	T	
	6	90472182	G	C	missense	ENST00000369393.3:c.2212C>G	ENSP00000358400.3:p.Gln738Glu	T3	93	5	5%	-	-	-	hmmpanther:PTRH22908:SF580	-	-	tolerated	T	T	
	6	90402239	G	A	missense	ENST00000369393.3:c.10510C>T	ENSP00000358400.3:p.Leu3504Phe	T7	39	4	9%	-	-	-	hmmpanther:PTRH22908:SF580	-	-	deleterious	T	T	
PKHD11	8	110432873	A	T	missense	ENST00000378402.5:c.2651A>T	ENSP00000367655.5:p.Tyr884Phe	T1	127	8	6%	-	-	-	hmmpanther:PTRH11915&hmn	-	-	tolerated	T	T	
	8	110535503	G	T	missense	ENST00000378402.5:c.12372G>T	ENSP00000367655.5:p.Arg4124Ser	T2	57	3	5%	-	-	-	-	-	-	tolerated	T	T	
	8	110445445	G	T	stop gained	ENST00000378402.5:c.3340G>T	ENSP00000367655.5:p.Glu1114Ter	T3	81	6	7%	-	-	-	hmmpanther:PTRH11915&hmn	-	-	-	-	-	
PPP2R3A	3	135722018	G	T	missense	ENST00000264977.3:c.1678G>T	ENSP00000264977.3:p.Val560Phe	T1	28	4	13%	-	-	-	hmmpanther:PTRH14095&hmn	-	-	tolerated_low_confu	T	T	
	3	135821011	G	T	missense	ENST00000264977.3:c.3090G>T	ENSP00000264977.3:p.Lys1030Asn	T3	252	12	5%	-	-	-	hmmpanther:PTRH14095&hmn	-	-	deleterious	T	T	
	3	135721626	A	G	missense	ENST00000264977.3:c.1286A>G	ENSP00000264977.3:p.Lys429Arg	T4	36	5	12%	-	-	-	hmmpanther:PTRH14095&hmn	-	-	tolerated_low_confu	T	T	
PTPRS	19	5212020	C	A	missense	ENST00000357368.4:c.5011G>T	ENSP00000349932.4:p.Val1671Leu	T1	65	6	8%	-	-	-	Superfamily_domains:SSF5279	-	-	tolerated	T	T	
	19	5220096	G	T	missense	ENST00000357368.4:c.3619C>A	ENSP00000349932.4:p.Pro1207Thr	T3	55	6	10%	-	-	-	hmmpanther:PTRH19134:SF200	-	-	deleterious	T	T	
	19	5286108	G	A	missense	ENST00000357368.4:c.44C>T	ENSP00000349932.4:p.Pro15Leu	T8	31	8	21%	-	-	-	Low_complexity_(Seg):seg&Tr	-	-	tolerated_low_confu	T	T	
SLC4A7	3	27436157	A	T	missense	ENST00000295736.5:c.2942T>A	ENSP00000295736.5:p.Ile981Lys	T3	131	7	5%	-	-	-	hmmpanther:PTRH11453&hmn	-	-	deleterious	D	D	
	3	27462214	T	C	missense	ENST00000295736.5:c.1462A>G	ENSP00000295736.5:p.Ile488Val	T4	139	8	6%	C:4.118e-05	-	5	hmmpanther:PTRH11453&hmn	-	-	tolerated	D	D	
	3	27444771	T	C	missense	ENST00000295736.5:c.2153A>G	ENSP00000295736.5:p.Tyr718Cys	T5c	41	3	7%	-	-	-	Transmembrane_helices:TMHe	-	-	deleterious	D	D	
AGAP2	12	58126185	C	T	splicing	ENST00000547588.1:c.1794+1G>A	ENST00000547588.1:c.1794+1G>A	T3	94	8	8%	-	-	-	-	-	-	-	-	-	
	12	58125655	C	T	missense	ENST00000547588.1:c.1910G>A	ENSP00000449241.1:p.Gly637Glu	T7	64	5	7%	-	-	-	hmmpanther:PTRH23180&hmn	-	-	tolerated	T	T	
DENND2C	1	115166127	C	A	splicing	ENST00000393274.1:c.943+1G>T	ENST00000393274.1:c.943+1G>T	T1	93	8	8%	-	-	-	-	-	-	-	-	-	
	1	115130518	C	A	missense	ENST00000357232.4:c.2234G>T	ENSP00000349768.3:p.Gly745Val	T3	113	8	7%	-	-	-	PROSITE_profiles:P550268&hmi						

Supplementary Table 5: Overlapped gemline variant genes in DNF data

Variants with deleterious, damaging, and/or pathogenic effect (see Suppl. Table 9)

Symbol	chr	LOC	Ref	Alt	Consequences	Impact	GMAF	ExAC_AC	Patient	HGVSc	HGVSp	ClinVar (2019)	SIFT	MetaLR	MetaSVM
AC079612.1	chr2	240498659	C	T	upstream_gene_variant	MODIFIER T:0.0008			patient8_tumor_syn4985	-	-		-	-	-
AC079612.1	chr2	240505863	G	A	3_prime_UTR_variant	MODIFIER A:0.0008			patient6_tumor_syn4985	ENST00000358775.1:c.*1059G>A	-	-	-	-	-
ANKK1	chr11	113270124	G	A	missense_variant	MODERA A:0.0072	A:3.253e-03		patient2_tumor_syn4985	ENST00000303941.3:c.1433G>A	ENSP00000306678.3:p.Arg478Gln		tolerated	T	T
ANKK1	chr11	113270178	C	A	missense_variant	MODERA A:0.0072	A:3.272e-03		patient2_tumor_syn4985	ENST00000303941.3:c.1487C>A	ENSP00000306678.3:p.Trp496Asn		deleterious	D	D
ANKRD30A	chr10	37455581	G	A	missense_variant	MODERATE	A:7.236e-05		patient6_tumor_syn4985	ENST00000361713.1:c.1945G>A	ENSP00000354432.1:p.Ala649Thr		tolerated	T	T
ANKRD30A	chr10	37481992	A	G	missense_variant&splice	MODERA G:0.0042	G:1.838e-03		patient2_tumor_syn4985	ENST00000361713.1:c.2345A>G	ENSP00000354432.1:p.Glu782Gly		deleterious	T	T
ATM	chr11	108153488	A	G	missense_variant	MODERATE	G:3.295e-05		patient11_tumor_syn4985	ENST00000278616.4:c.3628A>G	ENSP00000278616.4:p.Met1210Val	Uncertain_significance	tolerated	T	T
ATM	chr11	108188136	G	A	missense_variant	MODERA A:0.0028	A:2.570e-03		patient8_tumor_syn4985	ENST00000278616.4:c.6235G>A	ENSP00000278616.4:p.Val2079Ile	Benign/Likely_benign	tolerated	T	T
ATM	chr11	108198391	T	C	missense_variant	MODERA C:0.0072			patient8_tumor_syn4985	ENST00000278616.4:c.6995T>C	ENSP00000278616.4:p.Leu2332Pro	Benign/Likely_benign	tolerated	T	T
ATM	chr11	108236279	A	G	3_prime_UTR_variant	MODIFIER G:0.0028	G:2.398e-03		patient8_tumor_syn4985	ENST00000278616.4:c.*44A>G	-	Uncertain_significance	-	-	-
ATM	chr11	108236471	C	T	3_prime_UTR_variant	MODIFIER T:0.0028			patient8_tumor_syn4985	ENST00000278616.4:c.*236C>T	-	Uncertain_significance	-	-	-
CELSR2	chr1	109794593	C	T	missense_variant	MODERA T:0.0012	T:3.904e-03		patient1_tumor_syn4985	ENST00000271332.3:c.1892C>T	ENSP00000271332.3:p.Trp631Met		deleterious	T	T
CELSR2	chr1	109807571	C	T	missense_variant	MODERA T:0.0056	T:1.540e-03		patient11_tumor_syn4985	ENST00000271332.3:c.5546C>T	ENSP00000271332.3:p.Ala1849Val		tolerated	D	T
CELSR2	chr1	109816898	C	G	3_prime_UTR_variant	MODIFIER G:0.0058			patient3_tumor_syn4987	ENST00000271332.3:c.*227C>G	-	-	-	-	-
CELSR2	chr1	109817633	A	G	3_prime_UTR_variant	MODIFIER G:0.0054			patient3_tumor_syn4987	ENST00000271332.3:c.*962A>G	-	-	-	-	-
COL4A1	chr8	121267490	G	A	missense_variant	MODERA A:0.0028	A:5.247e-03		patient3_tumor_syn4987	ENST00000297848.3:c.2764G>A	ENSP00000297848.3:p.Val922Ile		tolerated	T	T
COL4A2	chr13	111114519	C	A	missense_variant	MODERA A:0.0054	A:1.506e-03		patient8_tumor_syn4985	ENST00000360467.5:c.1655C>A	ENSP00000353654.5:p.Thr552Lys	Likely_benign	tolerated	T	T
COL4A2	chr13	111164467	G	A	missense_variant	MODERA A:0.0010	A:5.370e-04&T:8.26		patient8_tumor_syn4985	ENST00000360467.5:c.5068G>A	ENSP00000353654.5:p.Ala1690Thr	Likely_benign	tolerated	D	T
COL4A2	chr13	111164563	T	C	3_prime_UTR_variant	MODIFIER C:0.0088	C:2.905e-03		patient8_tumor_syn4985	ENST00000360467.5:c.*25T>C	-	-	-	-	-
CUBN	chr10	16893406	G	C	missense_variant	MODERA C:0.0078	A:3.295e-05&C:1.99		patient8_tumor_syn4985	ENST00000378333.4:c.9491C>G	ENSP00000367064.4:p.Ser3164Trp	Uncertain_significance	deleterious	T	T
CUBN	chr10	16960624	T	C	missense_variant	MODERA C:0.0028	C:1.063e-03		patient11_tumor_syn4985	ENST00000378333.4:c.6997A>G	ENSP00000367064.4:p.Ile2333Val	Uncertain_significance	tolerated	T	T
CUBN	chr10	17153023	C	T	missense_variant	MODERA T:0.0092	T:4.110e-03		patient2_tumor_syn4987	ENST00000378333.4:c.910G>A	ENSP00000367064.4:p.Glu304Lys	Uncertain_significance	deleterious	D	T
EML6	chr2	55197958	T	C	3_prime_UTR_variant	MODIFIER T:0.0036			patient3_tumor_syn4987	ENST00000356458.6:c.*727T>C	-	-	-	-	-
EML6	chr2	55198728	A	G	3_prime_UTR_variant	MODIFIER G:0.0030			patient9_tumor_syn4985	ENST00000356458.6:c.*1497A>G	-	-	-	-	-
FCGBP	chr19	40367555	C	T	missense_variant	MODERA T:0.0098	T:3.417e-03		patient3_tumor_syn4987	ENST00000221347.6:c.13405G>A	ENSP00000221347.5:p.Val4469Ile		tolerated	T	T
FCGBP	chr19	40430459	G	A	missense_variant	MODERA A:0.0002	A:2.638e-04		patient9_tumor_syn4985	ENST00000221347.6:c.1484C>T	ENSP00000221347.5:p.Ser495Leu		tolerated	T	T
KIFC1	chr6	33359736	C	G	5_prime_UTR_variant	MODIFIER G:0.0056	G:8.602e-03		patient4_tumor_syn4985	ENST00000428849.2:c.*-27C>G	-	-	-	-	-
KIFC1	chr6	33371806	G	A	missense_variant	MODERA A:0.0090	A:8.945e-03		patient6_tumor_syn4985	ENST00000428849.2:c.656G>A	ENSP00000393963.2:p.Arg219Gln		tolerated	T	T
KIFC1	chr6	33371806	G	A	missense_variant	MODERA A:0.0090	A:8.945e-03		patient4_tumor_syn4985	ENST00000428849.2:c.656G>A	ENSP00000393963.2:p.Arg219Gln		tolerated	T	T
KIFC1	chr6	33372689	C	T	missense_variant	MODERA T:0.0016	T:2.883e-03		patient4_tumor_syn4985	ENST00000428849.2:c.817C>T	ENSP00000393963.2:p.Arg273Trp		deleterious	T	T
MUC16	chr19	9014194	A	T	missense_variant	MODERATE	T:3.307e-05		patient11_tumor_syn4985	ENST00000397910.4:c.38454T>A	ENSP00000381008.2:p.His12818Gln		-	T	T
MUC16	chr19	9010991	C	T	missense_variant	MODERATE	T:1.655e-05&G:8.27		patient6_tumor_syn4985	ENST00000397910.4:c.38927G>A	ENSP00000381008.2:p.Ser12976Asn		-	T	T
MUC16	chr19	9010991	C	T	missense_variant	MODERATE	T:1.655e-05&G:8.27		patient2_tumor_syn4985	ENST00000397910.4:c.38927G>A	ENSP00000381008.2:p.Ser12976Asn		-	T	T
MUC16	chr19	9009614	T	C	missense_variant	MODERATE	C:4.961e-05&G:8.26		patient4_tumor_syn4985	ENST00000397910.4:c.39112A>G	ENSP00000381008.2:p.Thr13038Ala		-	T	T
MUC16	chr19	8993008	G	C	missense_variant&splice	MODERA C:0.0092	C:2.970e-03		patient8_tumor_syn4985	ENST00000397910.4:c.41751C>G	ENSP00000381008.2:p.Ser13917Arg		-	T	T
NF1	chr17	29486054	A	T	missense_variant	MODERA A:0.0002	T:3.295e-05&G:8.23		patient8_tumor_syn4985	ENST00000358273.4:c.231A>T	ENSP00000351015.4:p.Lys77Asn	Uncertain_significance	deleterious	T	T
NF1	chr17	29497003	C	T	stop_gained	HIGH	T:8.238e-06		patient8_tumor_syn4985	ENST00000358273.4:c.574C>T	ENSP00000351015.4:p.Arg192Ter	Pathogenic	-	-	-
NF1	chr17	29541542	A	G	missense_variant	MODERATE	G:1.647e-05		patient5_tumor_syn4985	ENST00000358273.4:c.1466A>G	ENSP00000351015.4:p.Tyr489Cys	Pathogenic	tolerated	T	T
NF1	chr17	29588751	C	T	stop_gained	HIGH	T:8.236e-06		patient9_tumor_syn4985	ENST00000358273.4:c.4600C>T	ENSP00000351015.4:p.Arg1534Ter	Pathogenic/Likely_path	-	-	-
NF1	chr17	29702631	A	G	3_prime_UTR_variant	MODIFIER G:0.0094			patient11_tumor_syn4985	ENST00000358273.4:c.*1458A>G	-	-	-	-	-
OBSCN	chr1	228404401	A	G	missense_variant&splice	MODERA G:0.0002	G:9.381e-05		patient11_tumor_syn4985	ENST00000570156.2:c.2375A>G	ENSP00000455507.2:p.Gln792Arg		tolerated	T	T
OBSCN	chr1	228468437	G	A	missense_variant	MODERA A:0.0034	A:1.034e-03		patient11_tumor_syn4985	ENST00000570156.2:c.9424G>A	ENSP00000455507.2:p.Ala3142Thr		tolerated	T	T
OBSCN	chr1	228470764	C	T	missense_variant	MODERA T:0.0092	T:2.089e-03		patient11_tumor_syn4985	ENST00000570156.2:c.9803C>T	ENSP00000455507.2:p.Ala3268Val		tolerated	T	T
OBSCN	chr1	228481916	C	T	missense_variant	MODERATE	A:8.256e-06&T:2.47		patient10_tumor_syn4985	ENST00000570156.2:c.12482C>T	ENSP00000455507.2:p.Thr4161Met		tolerated	T	T
OBSCN	chr1	228509861	C	T	missense_variant	MODERA T:0.0002	T:1.652e-04		patient11_tumor_syn4985	ENST00000570156.2:c.18190C>T	ENSP00000455507.2:p.Pro6064Ser		tolerated	T	T
OBSCN	chr1	228511241	G	A	missense_variant	MODERATE	A:4.948e-05		patient3_tumor_syn4987	ENST00000570156.2:c.18457G>A	ENSP00000455507.2:p.Val6153Ile		deleterious	T	T
OBSCN	chr1	228557680	C	A	missense_variant	MODERA A:0.0010	A:1.901e-04		patient2_tumor_syn4987	ENST00000570156.2:c.22876C>A	ENSP00000455507.2:p.Arg726Ser		deleterious	T	T
OBSCN	chr1	228560317	G	A	missense_variant	MODERATE	A:8.567e-04		patient4_tumor_syn4985	ENST00000570156.2:c.24709G>A	ENSP00000455507.2:p.Val8237Met		deleterious	T	T
PASK	chr2	242063458	C	T	missense_variant	MODERA T:0.0032	T:8.236e-06&T:9.44		patient4_tumor_syn4985	ENST00000358649.4:c.2810G>A	ENSP00000351475.4:p.Arg937His		deleterious	T	T
PKHD11	chr8	110418593	A	G	missense_variant	MODERA G:0.0020	G:3.450e-04		patient2_tumor_syn4987	ENST00000378402.5:c.1699A>G	ENSP00000367655.5:p.Ile567Val		tolerated	T	T
PKHD11	chr8	110432873	A	G	missense_variant	MODERA G:0.0014	G:2.185e-03		patient1_tumor_syn4985	ENST00000378402.5:c.2651A>G	ENSP00000367655.5:p.Tyr884Cys		tolerated	T	T
PKHD11	chr8	110450593	G	T	missense_variant	MODERA T:0.0054	T:8.477e-03		patient4_tumor_syn4985	ENST00000378402.5:c.3668G>T	ENSP00000367655.5:p.Gly1223Val		deleterious	T	T
PKHD11	chr8	110450593	G	T	missense_variant	MODERA T:0.0054	T:8.477e-03		patient3_tumor_syn4987	ENST00000378402.5:c.3668G>T	ENSP00000367655.5:p.Gly1223Val		deleterious	T	T
PKHD11	chr8	110477066	C	T	stop_gained	HIGH	T:1.333e-03		patient9_tumor_syn4985	ENST00000378402.5:c.8005C>T	ENSP00000367655.5:p.Gln2669Ter		-	-	-
RGPD4	chr2	108443503	G	C	missense_variant	MODERA C:0.0078	A:8.326e-06&C:7.80		patient4_tumor_syn4985	ENST00000408999.3:c.34G>C	ENSP00000386810.3:p.Val122Leu		deleterious	T	T
SLC14A2	chr18	43195469	G	A	5_prime_UTR_variant	MODIFIER A:0.0028			patient9_tumor_syn4985	ENST00000255226.6:c.-113G>A	-	-	-	-	-
SLC14A2	chr18	43262408	G	A	missense_variant	MODERA A:0.0052	A:8.195e-03&T:8.23		patient8_tumor_syn4985	ENST00000255226.6:c.2687G>A	ENSP00000255226.5:p.Arg896His		deleterious	T	T

End note: Highlighted sites are recurrent mutations showed in different PNF and DNF samples

End note: Highlighted sites are recurrent mutation with same site on same gene in different PNF (Ratner), DNF (Gosline) and PNF (Pemov) samples.

Yellow: Overlapped mutated sites between PNF (Ratner) and DNF (Gosline)

Orange: Overlapped mutated sites between three datasets.

Supplementary Table 6: Overlapped somatic variant genes in DNF data

												Variants with deleterious, damaging, and/or pathogenic effect			
Symbol	chr	LOC	Ref	Alt	Consequences	Impact	GMAF	Patient	HGVSc	HGVSp	COSMIC	ClinVar	SIFT	MetaLR	MetaSVM
DMXL2	chr15	51798638	G	T	intron_variant	MODIFIER	T:0.0092	patient6	ENST00000543779.2:c.2764+693C>A		-	-	-	-	-
MACF1	chr1	39597015	T	A	intron_variant	MODIFIER	A:0.0034	patient10	ENST00000545844.1:c.220+46905T>A		-	-	-	-	-
MACF1	chr1	39597015	T	A	intron_variant	MODIFIER	A:0.0034	patient9	ENST00000545844.1:c.220+46905T>A		-	-	-	-	-
MACF1	chr1	39597015	T	A	intron_variant	MODIFIER	A:0.0034	patient9	ENST00000545844.1:c.220+46905T>A		-	-	-	-	-
MYH9	chr22	36673329	C	T	downstream_g	MODIFIER	T:0.0054	patient8	-		-	-	-	-	-

Supplemental Table7: Overlapped germline variant genes in PNF (Pemov et al, Re-analyzed with VarScan2)

SYMBOL	Patient	CHROM	POS	REF	ALT	Consequence	IMPACT	HGVSc	HGVSp	GMAF	ExAC_MAF	Existing_variation	CinVar (2019)	SIFT	MetaLR	MetaSV M	
ANKK1	p9	chr11	11326080	G	T	splice_acceptor_variant	HIGH	ENST00000303941.3:c.633-1G>T		T:0.006	T:2.440e-03	r139841238					
ANKRD30A	p23	chr10	3741292	G	T	stop_gained	HIGH	ENST00000361713.1:c.328G>T	ENSP0000034432.1:p.Glu110Ter	T:0.060	A:1.654e-05&T:0.012	r116939015					
	p24	chr10	3741292	G	T	stop_gained	HIGH	ENST00000361713.1:c.328G>T	ENSP0000034432.1:p.Glu110Ter	T:0.060	A:1.654e-05&T:0.012	r116939015					
	chr10	3743929	G	T	missense_variant	MODERATE	ENST00000361713.1:c.1232G>T	ENSP0000034432.1:p.Arg111Met		T:8.032e-04		r202149101		T&T	T	T	
	p5	chr10	3750586	G	T	missense_variant	MODERATE	ENST00000361713.1:c.1238G>C	ENSP0000034432.1:p.Val115Leu	T:0.004	T:4.114e-03	r5551835&COSM132707					
ATM	p27	chr11	10829676	C	G	missense_variant	MODERATE	ENST00000278616.4:c.198C>G	ENSP00000278616.4:p.Ser69Cys	G:0.0041	G:7.369e-03	r5880504		Benign/Likely_benig		D&D&D&D	
	p5	chr11	10812621	T	G	missense_variant	MODERATE	ENST00000278616.4:c.1880T>G	ENSP00000278616.4:p.Phe627Cys	G:0.0002	G:1.648e-05	r554608785		Uncertain_significance	T&T	T	
	p8	chr11	10812035	G	A	missense_variant	MODERATE	ENST00000278616.4:c.2218G>A	ENSP00000278616.4:p.Ala740Thr					Uncertain_significance	D&D&D	D	
	p16	chr11	10819894	C	A	missense_variant	MODERATE	ENST00000278616.4:c.699C>A	ENSP00000278616.4:p.Thr233Lys		A:6.589e-05&T:4.118e-03	r150509164		Conflicting_interpreta	D&D	T	
	chr11	10820123	C	T	missense_variant	MODERATE	ENST00000278616.4:c.7390T>C	ENSP00000278616.4:p.Cys264Arg		C:5.683e-04		r55801750&COSM758329		Conflicting_interpreta	T&T	T	
CELSR2	p22	chr1	15993126	G	A	missense_variant	MODERATE	ENST00000271332.3:c.425A>G	ENSP00000271332.3:p.Arg1420Gln							T	
	p10	chr1	109803697	G	A	missense_variant	MODERATE	ENST00000271332.3:c.3992G>A	ENSP00000271332.3:p.Arg1331His	A:0.0012	A:1.145e-03	r115077620				T	
	p8	chr1	109810200	G	A	missense_variant	MODERATE	ENST00000271332.3:c.6044G>A	ENSP00000271332.3:p.Arg2015Ile	A:0.0096	A:0.022	r57203203				D	
	p7	chr1	109811223	G	T	splice_donor_variant	HIGH	ENST00000271332.3:c.7483-1G>T								T	
COL14A1	p25	chr8	121256206	C	T	missense_variant	MODERATE	ENST00000297848.1:c.243C>G	ENSP00000297848.1:p.Thr313Met		T:4.655e-04	r1348211340				T&T&T&T	
COL4A2	chr8	111118344	C	T	splice_region_variant	LOW	ENST00000360467.5:c.1979-4C>T			T:0.0026	T:4.532e-03	r190632602				Likely_benign	
CUBN	p25	chr10	1687012	G	T	missense_variant	MODERATE	ENST00000377833.4:c.1065G>A	ENSP0000037064.4:p.Asn355Lys							Likely_benign	
	p17	chr10	16882363	G	A	missense_variant	MODERATE	ENST00000377833.4:c.999G>C	ENSP0000037064.4:p.Thr333Met		A:3.295e-05&T:1.647e-03	r1140637500				T&T	
	p9	chr10	1689486	G	C	missense_variant	MODERATE	ENST00000377833.4:c.981C>G	ENSP0000037064.4:p.Ser344Pro	C:0.0078	A:2.255e-05&C:1.993e-05	r57192244		Uncertain_significance	D	T	
	p27	chr10	1692184	G	A	missense_variant	MODERATE	ENST00000377833.4:c.871G>T	ENSP0000037064.4:p.Ala291Val	A:0.006	A:0.012	r5551835&COSM132707		Uncertain_significance	D	T	
	p12	chr10	16942831	C	A	missense_variant	MODERATE	ENST00000377833.4:c.820G>T	ENSP0000037064.4:p.Asp273Tyr		A:2.234e-04	r134802222		Uncertain_significance	D	T	
	p11	chr10	16955978	A	T	missense_variant	MODERATE	ENST00000377833.4:c.785T>A	ENSP0000037064.4:p.Asp245Glu	T:0.0026	T:5.650e-03	r111712856		Uncertain_significance	T	T	
	p8	chr10	16967417	T	C	missense_variant	MODERATE	ENST00000377833.4:c.646A>G	ENSP0000037064.4:p.Asn2157Asp	C:0.0032	C:5.610e-03	r134460241		Uncertain_significance	T	T	
	p10	chr10	16981015	T	C	missense_variant	MODERATE	ENST00000377833.4:c.658G>A	ENSP0000037064.4:p.Ile189Val	C:0.0050	C:1.293e-03	r57678990		Uncertain_significance	T	T	
	p16	chr10	17089963	C	T	missense_variant	MODERATE	ENST00000377833.4:c.373C>G	ENSP0000037064.4:p.Ser1251Thr	G:0.0064	G:1.756e-03	r115926680		Uncertain_significance	T	T	
FCGBP	p23	chr19	40354279	G	A	missense_variant	MODERATE	ENST00000221347.6:c.1619C>T	ENSP00000221347.6:p.Ala397Val		A:1.483e-04	r139845989				T	
	p24	chr19	40354279	G	A	missense_variant	MODERATE	ENST00000221347.6:c.1619C>T	ENSP00000221347.6:p.Ala397Val		A:1.483e-04	r139845989				T	
	p13	chr19	40357636	C	T	missense_variant	MODERATE	ENST00000221347.6:c.1567G>A	ENSP00000221347.6:p.Arg5226Gln	T:0.0002	T:8.236e-05	r202029040				T	
	p16	chr19	40376811	C	T	missense_variant	MODERATE	ENST00000221347.6:c.11611G>A	ENSP00000221347.6:p.Gly1871Arg	T:7.692e-03		r48402602				D	
	chr19	40376811	C	T	missense_variant	MODERATE	ENST00000221347.6:c.11611G>A	ENSP00000221347.6:p.Gly1871Arg		T:7.692e-03		r48402602				D	
	p22	chr19	40376811	C	T	missense_variant	MODERATE	ENST00000221347.6:c.11611G>A	ENSP00000221347.6:p.Gly1871Arg		T:7.692e-03		r48402602				D
	p17	chr19	40377117	C	T	missense_variant	MODERATE	ENST00000221347.6:c.11305G>A	ENSP00000221347.6:p.Ala379Met	T:0.0004	T:1.226e-04	r534122657				T	
	p22	chr19	40392008	G	A	missense_variant	MODERATE	ENST00000221347.6:c.8378C>T	ENSP00000221347.6:p.Ala379Val		A:6.611e-05	r20102036&COSM3823077				T	
	p25	chr19	40392008	G	A	missense_variant	MODERATE	ENST00000221347.6:c.8378C>T	ENSP00000221347.6:p.Ala379Val		A:6.611e-05	r20102036&COSM3823077				T	
	chr19	40392008	G	A	missense_variant	MODERATE	ENST00000221347.6:c.8378C>T	ENSP00000221347.6:p.Ala379Val		A:6.611e-05		r20102036&COSM3823077				T	
	p29	chr19	40392008	G	A	missense_variant	MODERATE	ENST00000221347.6:c.8378C>T	ENSP00000221347.6:p.Ala379Val		A:6.611e-05	r20102036&COSM3823077				T	
	p11	chr19	40392339	G	T	missense_variant	MODERATE	ENST00000221347.6:c.8165C>A	ENSP00000221347.6:p.Pro722His		A:1.395e-04&T:2.092e-03	r578269913				D	
	p16	chr19	40399385	C	T	missense_variant	MODERATE	ENST00000221347.6:c.6310G>A	ENSP00000221347.6:p.Gly1204Arg		T:9.734e-03	r201188964&COSM1481055				T	
	chr19	40399385	C	T	missense_variant	MODERATE	ENST00000221347.6:c.6310G>A	ENSP00000221347.6:p.Gly1204Arg		T:9.734e-03		r201188964&COSM1481055				T	
	p7	chr19	40399385	C	T	missense_variant	MODERATE	ENST00000221347.6:c.6310G>A	ENSP00000221347.6:p.Gly1204Arg		T:9.734e-03	r201188964&COSM1481055				T	
	p25	chr19	40402335	G	C	missense_variant	MODERATE	ENST00000221347.6:c.6154C>G	ENSP00000221347.6:p.Gln1722Glu		C:0.029	r57247426				T	
	p16	chr19	40408806	C	T	missense_variant	MODERATE	ENST00000221347.6:c.4033G>A	ENSP00000221347.6:p.Gly1345Ser	T:0.0004	T:9.890e-05&T:9.890e-03	r57601714&rs148703638				T	
	p16	chr19	40411643	C	T	missense_variant	MODERATE	ENST00000221347.6:c.3985G>A	ENSP00000221347.6:p.Val1329Ile	T:0.0012	T:6.919e-04	r134826512				T	
	chr19	40420097	C	A	missense_variant	MODERATE	ENST00000221347.6:c.2897G>T	ENSP00000221347.6:p.Gly196Val	A:0.0010	A:5.177e-04	r1144899113				D		
KIF1C	p25	chr5	31271778	A	A	missense_variant	MODERATE	ENST00000328819.2:c.638C>A	ENSP00000309363.1:p.Arg210Ser							D	
MA3T4	p6	chr5	66055573	C	T	missense_variant	MODERATE	ENST00000403625.2:c.480C>T	ENSP00000385727.1:p.Arg1347Pro	T:9.099e-04		r200785678				D&D&D&D&D	
	p10	chr5	66449319	G	T	stop_gained	HIGH	ENST00000403625.2:c.3559G>T	ENSP00000385727.1:p.Gly1187Ter							D	
	p16	chr5	66460352	G	A	missense_variant	MODERATE	ENST00000403625.2:c.5345G>A	ENSP00000385727.1:p.Arg1782Lys	A:0.0016	A:4.791e-03	r115455153		D&D&D&D&D	T		
	p17	chr5	66460390	G	A	missense_variant	MODERATE	ENST00000403625.2:c.5383G>A	ENSP00000385727.1:p.Val1795Ile	A:0.0098	A:0.01981&1.655e-05	r117221458				T	
	p21	chr5	66460390	G	A	missense_variant	MODERATE	ENST00000403625.2:c.5383G>A	ENSP00000385727.1:p.Val1795Ile	A:0.0098	A:0.01981&1.655e-05	r117221458				T	
	p22	chr5	66460390	G	A	missense_variant	MODERATE	ENST00000403625.2:c.5383G>A	ENSP00000385727.1:p.Val1795Ile	A:0.0098	A:0.01981&1.655e-05	r117221458				T	
	p19	chr5	66461713	A	G	missense_variant	MODERATE	ENST00000403625.2:c.6706A>G	ENSP00000385727.1:p.Ser2236Gly	G:0.0058	G:1.680e-03	r56602793		T&T&T&T	T		
	p12	chr5	66462640	A	G	missense_variant	MODERATE	ENST00000403625.2:c.7833A>G	ENSP00000385727.1:p.Ser2543Gly		G:8.289e-06	r578737257				T	
MROH2B	p9	chr5	41008777	G	A	missense_variant	MODERATE	ENST00000399564.4:c.359C>T	ENSP00000382476.4:p.Thr1180Ile	A:0.0088	A:2.000e-03	r34245444				D&D&D	
	p16	chr5	41047826	G	A	missense_variant	MODERATE	ENST00000399564.4:c.125G>T	ENSP00000382476.4:p.Thr320Ile			r37501963				D&D&D	
NF1	p6	chr17	29496957	T	A	missense_variant	MODERATE	ENST00000358273.4:c.538T>A	ENSP00000351015.4:p.Asp176Glu	A:0.0008	A:3.270e-03	r311236998&COSM24498		Conflicting_interpreta	T	T	
	p17	chr17	29496994	A	T	stop_gained	HIGH	ENST00000358273.4:c.565A>T	ENSP00000351015.4:p.Lys189Ter							D	
	p29	chr17	29528480	T	C	missense_variant	MODERATE	ENST00000358273.4:c.1237T>C	ENSP00000351015.4:p.Ser413Pro							Pathogenic	
	p6	chr17	29541596	T	T	frameshift_variant	HIGH	ENST00000358273.4:c.1521dupG	ENSP00000351015.4:p.Leu501a1Ter3							D	
	p13	chr17	29542629	G	T	stop_gained	HIGH	ENST00000358273.4:c.1521dupG	ENSP00000351015.4:p.Leu501a1Ter3							Pathogenic	
	p13	chr17	29550488	A	G	missense_variant	MODERATE	ENST00000358273.4:c.1748A>G	ENSP00000351015.4:p.Lys583Arg			r199474766&COSM36663		Pathogenic/Likely_patho	T&T	T	
	p7	chr17	29554235	G	C	splice_acceptor_variant	HIGH	ENST00000358273.4:c.2252-1G>C				r587781577				Likely_pathogenic	
	p10	chr17	2956079	C	T	stop_gained	HIGH	ENST00000358273.4:c.2446C>T	ENSP00000351015.4:p.Arg161Ter								

Supplemental Table 8: Somatic variant genes overlapped with PNF (Pemov et al, Re-analyzed with VarScan2)

SYMBOL	Patient	#CHROM	POS	REF	ALT	Consequence	IMPACT	HGVSc	HGVSp	GMAF	ExAC_MAF	Existing_variation	ClinVar (2019)	SIFT	MetaLR	MetaSVM
DOCK10	p22	chr2	225750388	C	A	missense_variant	MODERATE	NST00000258390.7:c.747G>	ENSP00000258390.7:p.Gln249His					D&D	D	T
NF1	p13	chr17	29483036	CAA	C	frameshift_variant	HIGH	T00000358273.4:c.98_99de	ENSP00000351015.4:p.Lys33SerfsTer4							
	p7	chr17	29527590	C	T	stop_gained	HIGH	VST00000358273.4:c.1039C	ENSP00000351015.4:p.Gln347Ter			COSM1479414&COSM1479413	Pathogenic			
	p9	chr17	29556992	G	A	missense_variant	MODERATE	IST00000358273.4:c.2990G>	ENSP00000351015.4:p.Arg997Lys					T&T&T	T	T
	p23	chr17	29654553	C	T	stop_gained	HIGH	VST00000358273.4:c.5305C	ENSP00000351015.4:p.Arg1769Ter			COSM36883&COSM303874	Pathogenic			
	p10	chr17	29665110	C	T	stop_gained	HIGH	VST00000358273.4:c.6772C	ENSP00000351015.4:p.Arg2258Ter			COSM1324055&COSM215676	Pathogenic			
OBSCN	p15	chr17	29683983	C	T	stop_gained	HIGH	VST00000358273.4:c.7744C	ENSP00000351015.4:p.Gln2582Ter							
	p19	chr1	228465551	G	T	missense_variant	MODERATE	VST00000570156.2:c.8138G>	ENSP00000455507.2:p.Arg2713Leu					T&T&T	T	T
	p17	chr1	228486163	G	T	missense_variant	MODERATE	IST00000570156.2:c.12955G>	ENSP00000455507.2:p.Ala4319Ser	T:8.361e-0		rs765653440		T&T	T	T
	p22	chr1	228504457	G	T	missense_variant	MODERATE	IST00000570156.2:c.16204G>	ENSP00000455507.2:p.Ala5402Ser					T&T&T&T	T	T
RREB1	p25	chr1	228564931	C	A	missense_variant	MODERATE	ST00000570156.2:c.26089C	ENSP00000455507.2:p.His8697Asn						T	T
	p17	chr6	7246860	G	T	stop_gained	HIGH	VST00000379938.2:c.4177G>	ENSP00000369270.2:p.Glu1393Ter							

LOH variants (Pemov et al, Re-analyzed with VarScan2)

SYMBOL	Patient	#CHROM	POS	REF	ALT	Consequence	IMPACT	HGVSc	HGVSp	GMAF	ExAC_MAF	Existing_variation	ClinVar (2019)	SIFT	MetaLR	MetaSVM
ATM	p29	chr11	108124761	T	C	missense_variant	MODERATE	VST00000278616.4:c.2119T>	ENSP00000278616.4:p.Ser707Pro	C:0.0044	:7.808e-0	rs4986761&COSM41595	Benign/Li	T&T&T	T	T
FCGBP	p7	chr19	40374034	A	G	missense_variant	MODERATE	IST00000221347.6:c.12044T	ENSP00000221347.5:p.Val4015Ala	G:0.504&G:0.46009	&rs138587194&COSM439495		T	T	T	
MDN1	p10	chr6	90408618	T	C	missense_variant	MODERATE	IST00000369393.3:c.9134A>	ENSP00000358400.3:p.Glu3045Gly	C:0.0014	:1.095e-0	rs116103426		T&T	T	T
NF1	p5	chr17	29550493	TTAAC	T	frameshift_variant	HIGH	000358273.4:c.1756_1759d	VSP00000351015.4:p.Thr586ValfsTer18				Pathogenic			

Supplemental Table 9:Disease-causing

	Methods	Category	Description
ClinVar clinical significance	Repository	unknown, untested, non-pathogenic, probable-non-pathogenic, probable-pathogenic, lkey-pathogenic, pathogenic , drug-response,histocompatibility, other	asserted to be pathogenic or likely pathogenic by at least one submitter
SIFT	P(An amino acid at a position is tolerated The most frequentest amino acid being tolerated)	D: Deleterious (sift<=0.05) ; T: tolerated (sift>0.05)	protein function based on sequence homology and the physico-chemical similarity between the alternate amino acids
MetaLR	Logistic regression	D: Deleterious ; T: Tolerated; higher scores are more deleterious	Ensemble score
MetaSVM	Support vector machine	D: Deleterious ; T: Tolerated; higher scores are more deleterious	Ensemble score